Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 101–200 of 1,000
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
Self-citationCaspofungin Therapy of Neonates With Invasive Candidiasis
Odio, C. M., Araya, R., Pinto, L. E., Castro, C. E., Vasquez, S., Alfaro, B., Sàenz, A., Herrera, M. L., & Walsh, T. J. (2004) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000145408.51526.0a · Cited by 202
Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review
Bochud, P.-Y., Bonten, M., Marchetti, O., & Calandra, T. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000143118.41100.14 · Cited by 201
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 193
Denning, D. W., Kibbler, C. C., & Barnes, R. A. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00580-2 · Cited by 194
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192
Pfaller, M. A., Diekema, D. J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.-C., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 194
Initial antimicrobial management of sepsis
Niederman, M. S., Baron, R. M., Bouadma, L., Calandra, T., Daneman, N., DeWaele, J., Kollef, M. H., Lipman, J., & Nair, G. B. (2021) · Critical Care · doi:10.1186/s13054-021-03736-w · Cited by 180
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Clinical hepatotoxicity associated with antifungal agents
Kyriakidis, I., Tragiannidis, A., Munchen, S., & Groll, A. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1270264 · Cited by 187
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 184
Chen, S. C. A., & Sorrell, T. C. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01313.x · Cited by 175
Intensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
Comparison of echinocandin antifungals
Eschenauer, G., DePestel, D. D., & Carver, P. L. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.71 · Cited by 186
Epidemiology and treatment approaches in management of invasive fungal infections
Ito, J. I., Kriengkauykiat, Dadwal, S., & Kriengkauykiat (2011) · Clinical Epidemiology · doi:10.2147/clep.s12502 · Cited by 203
Kullberg, B. J., Viscoli, C., Pappas, P. G., Vazquez, J., Ostrosky-Zeichner, L., Rotstein, C., Sobel, J. D., Herbrecht, R., Rahav, G., Jaruratanasirikul, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy827 · Cited by 182
Self-citationKrause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 179
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
“Whereas MIC data from clinical trials (18, 33, 35, 37) and population-based surveillance (22) show a restricted range of 0.”
MethodChaves, F., Garnacho-Montero, J., del Pozo, J. L., Bouza, E., Capdevila, J. A., de Cueto, M., Domínguez, M. Á., Esteban, J., Fernández-Hidalgo, N., Fernández Sampedro, M., et al. (2018) · Medicina Intensiva · doi:10.1016/j.medin.2017.09.012 · Cited by 170
Chamilos, G., Lewis, R. E., Albert, N., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-07 · Cited by 171
Wang, J.-L., Chang, C.-H., Young-Xu, Y., & Chan, K. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01657-09 · Cited by 167
Mattiuzzi, G. N., Alvarado, G., Giles, F. J., Ostrosky-Zeichner, L., Cortes, J., O'Brien, S., Verstovsek, S., Faderl, S., Zhou, X., Raad, I. I., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.143-147.2006 · Cited by 168
Oral care practices in intensive care units: a survey of 59 European ICUs
Rello, J., Koulenti, D., Blot, S., Sierra, R., Diaz, E., De Waele, J. J., Macor, A., Agbaht, K., & Rodriguez, A. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0605-3 · Cited by 167
Spanakis, E. K., Aperis, G., & Mylonakis, E. (2006) · Clinical Infectious Diseases · doi:10.1086/507891 · Cited by 167
Current challenges in the management of invasive fungal infections
Lai, C.-C., Tan, C.-K., Huang, Y.-T., Shao, P.-L., & Hsueh, P.-R. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0595-7 · Cited by 165
Aslam, S., Rotstein, C., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13623 · Cited by 160
Self-citationLouie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 164
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
Nami, S., Aghebati-Maleki, A., Morovati, H., & Aghebati-Maleki, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.009 · Cited by 160
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 160
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
Adjuvant Corticosteroid Therapy for Chronic Disseminated Candidiasis
Legrand, F., Lecuit, M., Dupont, B., Bellaton, E., Huerre, M., Rohrlich, P.-S., & Lortholary, O. (2008) · Clinical Infectious Diseases · doi:10.1086/527390 · Cited by 157
“More recently, voriconazole and caspofungin have also been used, with encouraging results and better tolerance than polyenes [7, 21, 22].”
BackgroundColombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., de Queiroz-Telles, F., Salles, M. J. C., da Cunha, C. A., Yasuda, M. A. S., Moretti, M. L., & Nucci, M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.02.001 · Cited by 153
Self-citationClinical pharmacology of antifungal compounds
Groll, A. H., Gea‐Banacloche, J., Glasmacher, A., Just‐Nübling, G., Maschmeyer, G., & Walsh, T. J. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00068-5 · Cited by 165
Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study
Balkovec, J. M., Hughes, D. L., Masurekar, P. S., Sable, C. A., Schwartz, R. E., & Singh, S. B. (2013) · Natural Product Reports · doi:10.1039/c3np70070d · Cited by 160
Self-citationWild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1068-1071.2003 · Cited by 154
Herbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A. J., Meert, L., Paesmans, M., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.334 · Cited by 149
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N., Desnos-Ollivier, M., Garcia-Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, E. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 150
What is the current and future status of conventional amphotericin B?
Kleinberg, M. E. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.013 · Cited by 171
Caspofungin: the first in a new class of antifungal agents
Kartsonis, N. A., NIELSEN, J. B. K., & Douglas, C. M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00064-5 · Cited by 149
Self-citationEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest, G. N., Weekes, E., & Johnson, J. K. (2008) · Journal of Infection · doi:10.1016/j.jinf.2007.10.014 · Cited by 144
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00082-5 · Cited by 152
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Cornely, O. A., Gachot, B., Akan, H., Bassetti, M., Uzun, O., Kibbler, C., Marchetti, O., de Burghgraeve, P., Ramadan, S., Pylkkanen, L., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ293 · Cited by 142
Thompson, G. R., Cadena, J., & Patterson, T. F. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.001 · Cited by 165
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma
Stone, J. A., Xu, X., Winchell, G. A., Deutsch, P. J., Pearson, P. G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A., Sandhu, P., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.815-823.2004 · Cited by 139
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., & Motyl, M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138
Self-citationCaspofungin for the treatment of less common forms of invasive candidiasis
Cornely, O. A., Lasso, M., Betts, R., Klimko, N., Vazquez, J., Dobb, G., Velez, J., Williams-Diaz, A., Lipka, J., Taylor, A., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm169 · Cited by 137
Self-citationAntifungal serum concentration monitoring: an update
Goodwin, M. L., & Drew, R. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm389 · Cited by 141
Gravel, J., Opatrny, L., & Shapiro, S. (2007) · Clinical Trials · doi:10.1177/1740774507081223 · Cited by 136
MOFENSON, L. M., Oleske, J. M., Serchuck, L. K., Dyke, R. V., & Wilfert, C. (2005) · Clinical Infectious Diseases · doi:10.1086/427295 · Cited by 151
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134
“Clinical trials have demonstrated the effectiveness of these compounds for management of both mucosal and systemic candidiasis against all Candida species (10, 11, 29, 32 , 33, 38, 44, 46).”
BackgroundNew triazoles and echinocandins: mode of action,in vitro activity and mechanisms of resistance
Fera, M. T., La Camera, E., & De Sarro, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.67 · Cited by 136
Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age
Sáez-Llorens, X., Macias, M., Maiya, P., Pineros, J., Jafri, H. S., Chatterjee, A., Ruiz, G., Raghavan, J., Bradshaw, S. K., Kartsonis, N. A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00868-08 · Cited by 137
Self-citationThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
Infections in Patients with Hematological Cancer: Recent Developments
O'Brien, S., Blijlevens, N. M. A., Mahfouz, T. H., & Anaissie, E. J. (2003) · Hematology · doi:10.1182/asheducation-2003.1.438 · Cited by 149
Arendrup, M. C., Arikan-Akdagli, S., Jørgensen, K. M., Barac, A., Steinmann, J., Toscano, C., Arsenijevic, V. A., Sartor, A., Lass-Flörl, C., Hamprecht, A., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.001 · Cited by 123
Kontoyiannis, D. P., Torres, H. A., Chagua, M., Hachem, R., Tarrand, J. J., Bodey, G. P., & Raad, I. I. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410017563 · Cited by 130
Invasive Candida species infections: a 5 year population-based assessment
Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T., & Elsayed, S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki258 · Cited by 130
Recent advances and challenges in the treatment of invasive fungal infections
Shao, P., Huang, L., & Hsueh, P. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.07.019 · Cited by 149
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson, G. R., Jenks, J. D., Baddley, J. W., Lewis, J. S., Egger, M., Schwartz, I. S., Boyer, J., Patterson, T. F., Chen, S. C. ‐., Pappas, P. G., et al. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-23 · Cited by 165
Recent advances in antifungal chemotherapy
Petrikkos, G. L., & Skiada, A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.03.009 · Cited by 145
Colombo, A. L., Perfect, J. R., DiNubile, M. J., Bartizal, K. F., Motyl, M. R., Hicks, P. S., Lupinacci, R. J., Sable, C. A., & Kartsonis, N. A. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0973-8 · Cited by 141
Self-citationThe Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications
Wagner, C., Graninger, W., Presterl, E., & Joukhadar, C. (2006) · Pharmacology · doi:10.1159/000096348 · Cited by 125
Changing Strategies for the Management of Invasive Fungal Infections
Rapp, R. P. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.3.4s.33151 · Cited by 125
Kauffman, C. A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200510-110jh · Cited by 114
Fernández-Ruiz, M., Aguado, J. M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., Montejo, M., García-Rodríguez, J., Pemán, J., Ruiz Pérez de Pipaón, M., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu158 · Cited by 122
Böhme, A., Ruhnke, M., Buchheidt, D., Cornely, O. A., Einsele, H., Enzensberger, R., Hebart, H. F., Heinz, W., Junghanß, C., Karthaus, M., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0622-5 · Cited by 141
Caspofungin: A Review of its Use in the Treatment of Fungal Infections
McCormack, P. L., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565140-00009 · Cited by 145
Onyewu, C., Wormley, F. L., Perfect, J. R., & Heitman, J. (2004) · Infection and Immunity · doi:10.1128/iai.72.12.7330-7333.2004 · Cited by 121
Self-citationAlexander, B. D., Ashley, E. D., Reller, L. B., & Reed, S. D. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.10.011 · Cited by 120
Andes, D., Ambrose, P. G., Hammel, J. P., Van Wart, S. A., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119
Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1339-6 · Cited by 117
Self-citationA new era of antifungal therapy
Wingard, J. R., & Leather, H. L. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.09.014 · Cited by 123
Ullmann, A. J., Sanz, M. A., Tramarin, A., Barnes, R. A., Wu, W., Gerlach, B. A., Krobot, K. J., Gerth, W. C., & on behalf of the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators (2006) · Clinical Infectious Diseases · doi:10.1086/505969 · Cited by 115
Wilcock, B. C., Endo, M. M., Uno, B. E., & Burke, M. D. (2013) · Journal of the American Chemical Society · doi:10.1021/ja403255s · Cited by 117
Garnacho-Montero, J., Diaz-Martin, A., Garcia-Cabrera, E., Ruiz Perez de Pipaon, M., Hernandez-Caballero, C., & Lepe-Jimenez, J. A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks347 · Cited by 112
Shah, C. P., McKey, J., Spirn, M. J., & Maguire, J. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.133405 · Cited by 117
Masood, A., & Sallah, S. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.10.003 · Cited by 119
Cutaneous Fungal Infections in the Oncology Patient: Recognition and Management
Mays, S. R., Bogle, M. A., & Bodey, G. P. (2006) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200607010-00004 · Cited by 113
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“Prospective studies comparing echinocandins with amphotericin B for the treatment of candidiasis have shown similar efficacy of caspofungin and amphotericin B deoxycholate in the intention to treat analysis but superiority of caspofungin in the per-protocol analysis [20], and non-inferiority of micafungin versus lipos…”
BackgroundResultCandida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy
Arnold, C. J., Johnson, M., Bayer, A. S., Bradley, S., Giannitsioti, E., Miró, J. M., Tornos, P., Tattevin, P., Strahilevitz, J., Spelman, D., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04867-14 · Cited by 110
Cisneros, J. M., Cobo-Reinoso, J., Pujol, M., Rodríguez‐Baño, J., & Salavert, M. (2007) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(07)74242-8 · Cited by 163
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Chau, M., Kong, D. C. M., van Hal, S. J., Urbancic, K. F., Trubiano, J. A., Cassumbhoy, M., Wilkes, J., Cooper, C. M., Roberts, J. A., Marriott, D. J. E., et al. (2014) · Internal Medicine Journal · doi:10.1111/imj.12600 · Cited by 116
Echinocandins for Candidemia in Adults without Neutropenia
Bennett, J. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmct060052 · Cited by 109
Experience with Caspofungin in the Treatment of Persistent Fungemia in Neonates
Natarajan, G., Lulic‐Botica, M., Rongkavilit, C., Pappas, A., & Bedard, M. P. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211380 · Cited by 115
A survey of anti-fungal management in lung transplantation
Dummer, J. S., Lazariashvilli, N., Barnes, J., Ninan, M., & Milstone, A. P. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2003.09.028 · Cited by 109
HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN
Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G., & Kim, R. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003244 · Cited by 109
Amornphimoltham, P., Yuen, P. S. T., Star, R. A., & Leelahavanichkul, A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05581-y · Cited by 109
Zaoutis, T. E., Jafri, H. S., Huang, L.-M., Locatelli, F., Barzilai, A., Ebell, W., Steinbach, W. J., Bradley, J., Lieberman, J. M., Hsiao, C.-C., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-1158 · Cited by 108
Self-citationCaspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5729-5731.2003 · Cited by 107
Candida Infections in Solid Organ Transplantation
Silveira, F. P., & Kusne, S. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12114 · Cited by 113
Regulation of Candida albicans Hyphal Morphogenesis by Endogenous Signals
Kornitzer, D. (2019) · Journal of Fungi · doi:10.3390/jof5010021 · Cited by 106
Auberger, J., Lass‐Flörl, C., Ulmer, H., Nogler-Semenitz, E., Clausen, J., Gunsilius, E., Einsele, H., Gastl, G. A., & Nachbaur, D. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0184-2 · Cited by 110
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A., Finquelievich, J., Barnes, R., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 108
Self-citation
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.